Effect of Food on the Pharmacokinetics and Pharmacodynamics of a Novel Dual Delayed‐Release Formulation of Esomeprazole in Healthy Subjects

Abstract

AbstractA novel dual delayed‐release formulation (DR) of esomeprazole was developed to prolong the effect of esomeprazole inhibiting gastric acid secretion. This study investigated the effect of food on the pharmacokinetics (PK) and pharmacodynamics (PD) of DR esomeprazole. A randomized, open‐label, single‐dose, 2‐period, 2‐sequence crossover study was conducted in healthy Korean subjects. Subjects were orally administered a single dose of 40‐ mg DR esomeprazole in fasted and fed states in each period. PK and PD characteristics evaluated through continuous 24‐hour intragastric pH monitoring in fasted and fed states were compared between the 2 conditions. A total of 23 subjects completed the study and were included in the PK analysis. PD analysis was conducted in 21 subjects, excluding 2 subjects, because of inappropriate pH profiles. The systemic exposure of esomeprazole after a single dose of DR esomeprazole in the fed state decreased compared to that in the fasted state. However, the percentage decrease from baseline in integrated gastric acidity and the percentage of time at pH ≥4 were not significantly different between the 2 conditions. In conclusion, although the systemic exposure of esomeprazole decreased when DR esomeprazole was administered in the fed state compared to that in the fasted state, the degree of gastric acid secretion inhibition was not clinically different, regardless of food intake.